REGENXBIO reports three-year ALTITUDE results for sura-vec diabetic retinopathy program
REGENXBIO (NASDAQ:RGNX) announced three-year Phase II results from the ALTITUDE clinical trial evaluating investigational sura-vec for non-proliferative diabetic retinopathy (NPDR).










